VYNE Therapeutics Inc. (VYNE) 10-Year Financial Performance & Capital Metrics

VYNE • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Show more

Revenue $501K +18.2%
EBITDA -$44M -49.1%
Net Income -$40M -40.0%
EPS (Diluted) -0.94 +66.1%
Gross Margin 100%
EBITDA Margin -8709.18% -26.2%
Operating Margin -8709.98% -26.2%
Net Margin -7950.9% -18.5%
ROE -56.57% -19.2%
ROIC -72.26% +3.5%
Debt/Equity 0.00 -21.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y2.49%

3Y-18.66%

TTM6.29%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM9.3%

ROCE

10Y Avg-14.13%

5Y Avg19.97%

3Y Avg-65.06%

Latest-61.36%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	674K	4.58M	10.64M	443K	20.99M	931K	477K	424K	501K
Revenue Growth %	-	-	5.8%	1.32%	-0.96%	46.39%	-0.96%	-0.49%	-0.11%	0.18%
Cost of Goods Sold+	0	0	0	0	350K	1.39M	0	0	0	0
COGS % of Revenue	-	-	-	-	0.79%	0.07%	-	-	-	-
Gross Profit+	0	674K	4.58M	10.64M	93K	19.6M	931K	477K	424K	501K
Gross Margin %	-	1%	1%	1%	0.21%	0.93%	1%	1%	1%	1%
Gross Profit Growth %	-	-	5.8%	1.32%	-0.99%	209.76%	-0.95%	-0.49%	-0.11%	0.18%
Operating Expenses+	4.61M	15.01M	34.17M	65.17M	76.24M	-232.94M	39.84M	34.77M	29.68M	44.14M
OpEx % of Revenue	-	22.26%	7.46%	6.13%	172.1%	-11.1%	42.79%	72.9%	70%	88.1%
Selling, General & Admin	1.69M	3.75M	5.17M	12.19M	22.48M	89.54M	20.3M	16.39M	13.38M	13.19M
SG&A % of Revenue	-	5.57%	1.13%	1.15%	50.75%	4.27%	21.8%	34.35%	31.54%	26.33%
Research & Development	2.92M	11.26M	29.01M	52.99M	53.76M	43.53M	19.54M	18.39M	16.31M	30.95M
R&D % of Revenue	-	16.7%	6.33%	4.98%	121.36%	2.07%	20.99%	38.54%	38.46%	61.77%
Other Operating Expenses	0	0	0	0	0	-366.02M	0	0	0	0
Operating Income+	-4.61M	-14.33M	-29.59M	-54.53M	-76.24M	252.55M	-38.91M	-34.3M	-29.26M	-43.64M
Operating Margin %	-	-21.26%	-6.46%	-5.13%	-172.1%	12.03%	-41.79%	-71.9%	-69%	-87.1%
Operating Income Growth %	-	-2.11%	-1.06%	-0.84%	-0.4%	4.31%	-1.15%	0.12%	0.15%	-0.49%
EBITDA+	-4.61M	-14.33M	-29.59M	-54.51M	-75.89M	252.89M	-38.8M	-34.22M	-29.26M	-43.63M
EBITDA Margin %	-	-21.26%	-6.46%	-5.12%	-171.31%	12.05%	-41.68%	-71.75%	-69%	-87.09%
EBITDA Growth %	-	-2.11%	-1.06%	-0.84%	-0.39%	4.33%	-1.15%	0.12%	0.15%	-0.49%
D&A (Non-Cash Add-back)	0	4K	8K	22K	350K	341K	109K	72K	0	4K
EBIT	-4.61M	-14.33M	-29.59M	-54.53M	-94.43M	-251.44M	-38.91M	-34.3M	-29.26M	-43.64M
Net Interest Income+	0	264K	517K	3.09M	-921K	-4.39M	-5.61M	0	0	0
Interest Income	0	264K	517K	3.09M	0	0	0	0	0	0
Interest Expense	0	0	0	0	921K	4.39M	5.61M	0	0	0
Other Income/Expense	0	264K	517K	3.09M	-19.11M	-508.37M	-4.85M	363K	1.39M	3.83M
Pretax Income+	-4.61M	-14.07M	-29.08M	-51.45M	-73.7M	-255.83M	-43.76M	-33.93M	-27.87M	-39.8M
Pretax Margin %	-	-20.87%	-6.35%	-4.84%	-166.37%	-12.19%	-47%	-71.14%	-65.74%	-79.45%
Income Tax+	0	0	-8K	0	-3.24M	-258K	448K	13K	0	4K
Effective Tax Rate %	1%	1%	1%	1%	0.96%	1%	1.68%	0.68%	1.02%	1%
Net Income+	-4.61M	-14.07M	-29.08M	-51.45M	-70.46M	-255.57M	-73.33M	-23.21M	-28.45M	-39.83M
Net Margin %	-	-20.87%	-6.35%	-4.84%	-159.06%	-12.17%	-78.76%	-48.66%	-67.1%	-79.51%
Net Income Growth %	-	-2.05%	-1.07%	-0.77%	-0.37%	-2.63%	0.71%	0.68%	-0.23%	-0.4%
Net Income (Continuing)	-4.61M	-14.07M	-29.08M	-51.45M	-95.18M	-255.57M	-44.21M	-33.95M	-27.87M	-39.81M
Discontinued Operations	0	0	0	0	0	0	-29.12M	10.73M	-580K	-27K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-28.75	-46.49	-101.65	-170.94	-149.48	-141.90	-25.65	-10.65	-2.77	-0.94
EPS Growth %	-	-0.62%	-1.19%	-0.68%	0.13%	0.05%	0.82%	0.58%	0.74%	0.66%
EPS (Basic)	-28.75	-46.49	-101.65	-170.94	-149.48	-141.90	-25.65	-10.65	-2.77	-0.94
Diluted Shares Outstanding	160.27K	302.59K	286.04K	300.95K	471.39K	1.8M	2.86M	3.19M	10.27M	42.59M
Basic Shares Outstanding	160.27K	302.59K	286.04K	300.95K	471.39K	1.8M	2.86M	3.19M	10.27M	42.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	43.88M	31.54M	63.86M	139.5M	78.33M	87.26M	63.19M	38.27M	95.96M	64.44M
Cash & Short-Term Investments	43.81M	30.91M	62.48M	136.25M	76.94M	58.59M	42.25M	30.91M	93.25M	61.52M
Cash Only	43.81M	4.03M	10.21M	49.51M	30.78M	57.56M	42.25M	30.91M	30.62M	19.93M
Short-Term Investments	0	26.88M	49.3M	86.74M	46.17M	1.03M	0	0	62.63M	41.59M
Accounts Receivable	0	0	786K	0	0	15.82M	7.58M	5M	0	0
Days Sales Outstanding	-	-	62.61	-	-	275.04	2.97K	3.83K	-	-
Inventory	0	0	-2.98M	0	0	7.4M	7.29M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	1.94K	-	-	-	-
Other Current Assets	0	0	0	3.25M	0	855K	1.5M	240K	2.71M	2.92M
Total Non-Current Assets+	0	10.51M	3.01M	428K	842K	6.48M	3.86M	2.48M	1.72M	2.47M
Property, Plant & Equipment	0	27K	28K	146K	769K	2.14M	354K	0	207K	206K
Fixed Asset Turnover	-	24.96x	163.64x	72.88x	0.58x	9.82x	2.63x	-	2.05x	2.43x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	10.42M	2.98M	0	0	0	0	0	0	0
Other Non-Current Assets	0	66K	0	282K	73K	4.34M	3.51M	2.48M	1.51M	2.26M
Total Assets+	43.88M	42.05M	66.87M	139.93M	79.17M	93.74M	67.05M	40.76M	97.69M	66.91M
Asset Turnover	-	0.02x	0.07x	0.08x	0.01x	0.22x	0.01x	0.01x	0.00x	0.01x
Asset Growth %	-	-0.04%	0.59%	1.09%	-0.43%	0.18%	-0.28%	-0.39%	1.4%	-0.32%
Total Current Liabilities+	770K	3.9M	7.82M	9.54M	10.66M	21.77M	18.41M	9.35M	7.54M	14.82M
Accounts Payable	637K	1.53M	2.46M	3.29M	3.77M	4.78M	6.51M	2.39M	1.66M	2.71M
Days Payables Outstanding	-	-	-	-	3.93K	1.25K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	53K	308K	2.45M	3.6M	485K	4.78M	2.96M	2.58M	4.12M	2.74M
Current Ratio	56.99x	8.08x	8.17x	14.62x	7.35x	4.01x	3.43x	4.10x	12.73x	4.35x
Quick Ratio	56.99x	8.08x	8.55x	14.62x	7.35x	3.67x	3.04x	4.10x	12.73x	4.35x
Cash Conversion Cycle	-	-	-	-	-	963.09	-	-	-	-
Total Non-Current Liabilities+	59.07M	67.59M	116.08M	7K	0	34.48M	0	211K	1.41M	0
Long-Term Debt	0	0	0	0	0	33.17M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	853K	0	0	99K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	59.07M	59.06M	109.35M	7K	0	457K	0	211K	1.31M	0
Total Liabilities	59.84M	71.49M	123.9M	9.55M	10.66M	56.25M	18.41M	9.56M	8.95M	14.82M
Total Debt+	0	0	0	0	700K	34.78M	349K	0	214K	99K
Net Debt	-43.81M	-4.03M	-10.21M	-49.51M	-30.08M	-22.78M	-41.9M	-30.91M	-30.41M	-19.83M
Debt / Equity	-	-	-	-	0.01x	0.93x	0.01x	-	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	0.14x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-0.09x	-	-	-	-
Interest Coverage	-	-	-	-	-82.78x	57.53x	-6.94x	-	-	-
Total Equity+	-15.95M	-29.44M	-57.03M	130.38M	68.51M	37.49M	48.64M	31.2M	88.73M	52.09M
Equity Growth %	-	-0.85%	-0.94%	3.29%	-0.47%	-0.45%	0.3%	-0.36%	1.84%	-0.41%
Book Value per Share	-99.54	-97.30	-199.39	433.21	145.33	20.82	17.01	9.79	8.64	1.22
Total Shareholders' Equity	-15.95M	-29.44M	-57.03M	130.38M	68.51M	37.49M	48.64M	31.2M	88.73M	52.09M
Common Stock	1K	1K	1K	3K	3K	4K	5K	0	1K	1K
Retained Earnings	-16.05M	-30.11M	-59.19M	-110.64M	-184.34M	-566.2M	-639.52M	-662.74M	-691.34M	-731.17M
Treasury Stock	0	-699K	0	0	0	0	0	0	0	0
Accumulated OCI	-59M	-26K	-51K	-96K	24K	0	0	0	26K	20K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.18M	-2.29M	-28.25M	-52.73M	-65.1M	-137.08M	-56.37M	-29.2M	-25.34M	-33.97M
Operating CF Margin %	-	-3.4%	-6.16%	-4.96%	-146.95%	-6.53%	-60.54%	-61.22%	-59.77%	-67.81%
Operating CF Growth %	-	0.45%	-11.33%	-0.87%	-0.23%	-1.11%	0.59%	0.48%	0.13%	-0.34%
Net Income	-4.61M	-14.07M	-29.08M	-51.45M	-73.7M	-255.57M	-73.33M	-23.21M	-28.45M	-39.83M
Depreciation & Amortization	0	4K	8K	22K	700K	341K	109K	72K	0	4K
Stock-Based Compensation	65K	573K	1.45M	3.64M	6.7M	18.1M	8.08M	4.3M	3.31M	3.3M
Deferred Taxes	0	-573K	60K	0	0	56.3M	1.52M	0	0	0
Other Non-Cash Items	65K	705K	31K	-774K	-691K	84.07M	2.47M	-12.64M	-254K	-2.44M
Working Capital Changes	360K	11.07M	-722K	-4.17M	1.89M	-40.33M	4.78M	2.28M	60K	5M
Change in Receivables	0	0	-786K	786K	1.36M	-17.14M	7.71M	11.21M	405K	-899K
Change in Inventory	0	0	1.19M	2.76M	-1.36M	-6.05M	113K	97K	0	0
Change in Payables	0	889K	620K	825K	481K	-12.97M	-2.67M	-8.68M	-559K	6.01M
Cash from Investing+	0	-37.49M	-15.06M	-33.88M	41.37M	89.11M	1.03M	15.67M	-57.35M	23.36M
Capital Expenditures	0	-31K	-27K	-140K	-11K	-113K	0	0	0	-117K
CapEx % of Revenue	-	0.05%	0.01%	0.01%	0.02%	0.01%	-	-	-	0.23%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	25K	0	-40K	38.64M	0	0	0	0
Cash from Financing+	47.72M	0	49.49M	125.91M	4.99M	61.81M	39.78M	1.65M	82.39M	-141K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	98K	0	-833K	496K	465K	169K	228K	-28K	-67K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.18M	-2.32M	-28.27M	-52.87M	-65.11M	-137.19M	-56.37M	-29.2M	-25.34M	-34.09M
FCF Margin %	-	-3.45%	-6.17%	-4.97%	-146.98%	-6.54%	-60.54%	-61.22%	-59.77%	-68.04%
FCF Growth %	-	0.44%	-11.18%	-0.87%	-0.23%	-1.11%	0.59%	0.48%	0.13%	-0.35%
FCF per Share	-26.10	-7.67	-98.85	-175.68	-138.13	-76.18	-19.72	-9.17	-2.47	-0.80
FCF Conversion (FCF/Net Income)	0.91x	0.16x	0.97x	1.03x	0.92x	0.54x	0.77x	1.26x	0.89x	0.85x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-140.29%	-70.86%	-482.2%	-170.28%	-58.14%	-47.44%	-56.57%
Return on Invested Capital (ROIC)	-	-	-	-600.3%	-95.86%	712.8%	-272.12%	-731.86%	-74.86%	-72.26%
Gross Margin	-	100%	100%	100%	20.99%	93.37%	100%	100%	100%	100%
Net Margin	-	-2087.24%	-634.57%	-483.51%	-15906.09%	-1217.4%	-7876.37%	-4865.83%	-6710.38%	-7950.9%
Debt / Equity	-	-	-	-	0.01x	0.93x	0.01x	-	0.00x	0.00x
Interest Coverage	-	-	-	-	-82.78x	57.53x	-6.94x	-	-	-
FCF Conversion	0.91x	0.16x	0.97x	1.03x	0.92x	0.54x	0.77x	1.26x	0.89x	0.85x
Revenue Growth	-	-	579.82%	132.21%	-95.84%	4638.83%	-95.57%	-48.76%	-11.11%	18.16%

Revenue by Segment

	2020	2021	2022	2024
Reportable	-	-	-	501K
Reportable Growth	-	-	-	-
Royalty	791K	931K	477K	-
Royalty Growth	-	17.70%	-48.76%	-
Product	10.2M	13.82M	-	-
Product Growth	-	35.50%	-	-
License	10M	-	-	-
License Growth	-	-	-	-
Product and Service, Other	-	-	-	-
Product and Service, Other Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

VYNE Therapeutics Inc. (VYNE) reported $0.5M in revenue for fiscal year 2024.

VYNE Therapeutics Inc. (VYNE) grew revenue by 18.2% over the past year. This is strong growth.

VYNE Therapeutics Inc. (VYNE) reported a net loss of $33.7M for fiscal year 2024.

Dividend & Returns

VYNE Therapeutics Inc. (VYNE) has a return on equity (ROE) of -56.6%. Negative ROE indicates the company is unprofitable.

VYNE Therapeutics Inc. (VYNE) had negative free cash flow of $38.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

VYNE Therapeutics Inc. (VYNE) 10-Year Financial Performance & Capital Metrics

VYNE • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $501K +18.2%
EBITDA -$44M -49.1%
Net Income -$40M -40.0%
EPS (Diluted) -0.94 +66.1%
Gross Margin 100%
EBITDA Margin -8709.18% -26.2%
Operating Margin -8709.98% -26.2%
Net Margin -7950.9% -18.5%
ROE -56.57% -19.2%
ROIC -72.26% +3.5%
Debt/Equity 0.00 -21.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y2.49%

3Y-18.66%

TTM6.29%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM9.3%

ROCE

10Y Avg-14.13%

5Y Avg19.97%

3Y Avg-65.06%

Latest-61.36%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	674K	4.58M	10.64M	443K	20.99M	931K	477K	424K	501K
Revenue Growth %	-	-	5.8%	1.32%	-0.96%	46.39%	-0.96%	-0.49%	-0.11%	0.18%
Cost of Goods Sold+	0	0	0	0	350K	1.39M	0	0	0	0
COGS % of Revenue	-	-	-	-	0.79%	0.07%	-	-	-	-
Gross Profit+	0	674K	4.58M	10.64M	93K	19.6M	931K	477K	424K	501K
Gross Margin %	-	1%	1%	1%	0.21%	0.93%	1%	1%	1%	1%
Gross Profit Growth %	-	-	5.8%	1.32%	-0.99%	209.76%	-0.95%	-0.49%	-0.11%	0.18%
Operating Expenses+	4.61M	15.01M	34.17M	65.17M	76.24M	-232.94M	39.84M	34.77M	29.68M	44.14M
OpEx % of Revenue	-	22.26%	7.46%	6.13%	172.1%	-11.1%	42.79%	72.9%	70%	88.1%
Selling, General & Admin	1.69M	3.75M	5.17M	12.19M	22.48M	89.54M	20.3M	16.39M	13.38M	13.19M
SG&A % of Revenue	-	5.57%	1.13%	1.15%	50.75%	4.27%	21.8%	34.35%	31.54%	26.33%
Research & Development	2.92M	11.26M	29.01M	52.99M	53.76M	43.53M	19.54M	18.39M	16.31M	30.95M
R&D % of Revenue	-	16.7%	6.33%	4.98%	121.36%	2.07%	20.99%	38.54%	38.46%	61.77%
Other Operating Expenses	0	0	0	0	0	-366.02M	0	0	0	0
Operating Income+	-4.61M	-14.33M	-29.59M	-54.53M	-76.24M	252.55M	-38.91M	-34.3M	-29.26M	-43.64M
Operating Margin %	-	-21.26%	-6.46%	-5.13%	-172.1%	12.03%	-41.79%	-71.9%	-69%	-87.1%
Operating Income Growth %	-	-2.11%	-1.06%	-0.84%	-0.4%	4.31%	-1.15%	0.12%	0.15%	-0.49%
EBITDA+	-4.61M	-14.33M	-29.59M	-54.51M	-75.89M	252.89M	-38.8M	-34.22M	-29.26M	-43.63M
EBITDA Margin %	-	-21.26%	-6.46%	-5.12%	-171.31%	12.05%	-41.68%	-71.75%	-69%	-87.09%
EBITDA Growth %	-	-2.11%	-1.06%	-0.84%	-0.39%	4.33%	-1.15%	0.12%	0.15%	-0.49%
D&A (Non-Cash Add-back)	0	4K	8K	22K	350K	341K	109K	72K	0	4K
EBIT	-4.61M	-14.33M	-29.59M	-54.53M	-94.43M	-251.44M	-38.91M	-34.3M	-29.26M	-43.64M
Net Interest Income+	0	264K	517K	3.09M	-921K	-4.39M	-5.61M	0	0	0
Interest Income	0	264K	517K	3.09M	0	0	0	0	0	0
Interest Expense	0	0	0	0	921K	4.39M	5.61M	0	0	0
Other Income/Expense	0	264K	517K	3.09M	-19.11M	-508.37M	-4.85M	363K	1.39M	3.83M
Pretax Income+	-4.61M	-14.07M	-29.08M	-51.45M	-73.7M	-255.83M	-43.76M	-33.93M	-27.87M	-39.8M
Pretax Margin %	-	-20.87%	-6.35%	-4.84%	-166.37%	-12.19%	-47%	-71.14%	-65.74%	-79.45%
Income Tax+	0	0	-8K	0	-3.24M	-258K	448K	13K	0	4K
Effective Tax Rate %	1%	1%	1%	1%	0.96%	1%	1.68%	0.68%	1.02%	1%
Net Income+	-4.61M	-14.07M	-29.08M	-51.45M	-70.46M	-255.57M	-73.33M	-23.21M	-28.45M	-39.83M
Net Margin %	-	-20.87%	-6.35%	-4.84%	-159.06%	-12.17%	-78.76%	-48.66%	-67.1%	-79.51%
Net Income Growth %	-	-2.05%	-1.07%	-0.77%	-0.37%	-2.63%	0.71%	0.68%	-0.23%	-0.4%
Net Income (Continuing)	-4.61M	-14.07M	-29.08M	-51.45M	-95.18M	-255.57M	-44.21M	-33.95M	-27.87M	-39.81M
Discontinued Operations	0	0	0	0	0	0	-29.12M	10.73M	-580K	-27K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-28.75	-46.49	-101.65	-170.94	-149.48	-141.90	-25.65	-10.65	-2.77	-0.94
EPS Growth %	-	-0.62%	-1.19%	-0.68%	0.13%	0.05%	0.82%	0.58%	0.74%	0.66%
EPS (Basic)	-28.75	-46.49	-101.65	-170.94	-149.48	-141.90	-25.65	-10.65	-2.77	-0.94
Diluted Shares Outstanding	160.27K	302.59K	286.04K	300.95K	471.39K	1.8M	2.86M	3.19M	10.27M	42.59M
Basic Shares Outstanding	160.27K	302.59K	286.04K	300.95K	471.39K	1.8M	2.86M	3.19M	10.27M	42.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	43.88M	31.54M	63.86M	139.5M	78.33M	87.26M	63.19M	38.27M	95.96M	64.44M
Cash & Short-Term Investments	43.81M	30.91M	62.48M	136.25M	76.94M	58.59M	42.25M	30.91M	93.25M	61.52M
Cash Only	43.81M	4.03M	10.21M	49.51M	30.78M	57.56M	42.25M	30.91M	30.62M	19.93M
Short-Term Investments	0	26.88M	49.3M	86.74M	46.17M	1.03M	0	0	62.63M	41.59M
Accounts Receivable	0	0	786K	0	0	15.82M	7.58M	5M	0	0
Days Sales Outstanding	-	-	62.61	-	-	275.04	2.97K	3.83K	-	-
Inventory	0	0	-2.98M	0	0	7.4M	7.29M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	1.94K	-	-	-	-
Other Current Assets	0	0	0	3.25M	0	855K	1.5M	240K	2.71M	2.92M
Total Non-Current Assets+	0	10.51M	3.01M	428K	842K	6.48M	3.86M	2.48M	1.72M	2.47M
Property, Plant & Equipment	0	27K	28K	146K	769K	2.14M	354K	0	207K	206K
Fixed Asset Turnover	-	24.96x	163.64x	72.88x	0.58x	9.82x	2.63x	-	2.05x	2.43x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	10.42M	2.98M	0	0	0	0	0	0	0
Other Non-Current Assets	0	66K	0	282K	73K	4.34M	3.51M	2.48M	1.51M	2.26M
Total Assets+	43.88M	42.05M	66.87M	139.93M	79.17M	93.74M	67.05M	40.76M	97.69M	66.91M
Asset Turnover	-	0.02x	0.07x	0.08x	0.01x	0.22x	0.01x	0.01x	0.00x	0.01x
Asset Growth %	-	-0.04%	0.59%	1.09%	-0.43%	0.18%	-0.28%	-0.39%	1.4%	-0.32%
Total Current Liabilities+	770K	3.9M	7.82M	9.54M	10.66M	21.77M	18.41M	9.35M	7.54M	14.82M
Accounts Payable	637K	1.53M	2.46M	3.29M	3.77M	4.78M	6.51M	2.39M	1.66M	2.71M
Days Payables Outstanding	-	-	-	-	3.93K	1.25K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	53K	308K	2.45M	3.6M	485K	4.78M	2.96M	2.58M	4.12M	2.74M
Current Ratio	56.99x	8.08x	8.17x	14.62x	7.35x	4.01x	3.43x	4.10x	12.73x	4.35x
Quick Ratio	56.99x	8.08x	8.55x	14.62x	7.35x	3.67x	3.04x	4.10x	12.73x	4.35x
Cash Conversion Cycle	-	-	-	-	-	963.09	-	-	-	-
Total Non-Current Liabilities+	59.07M	67.59M	116.08M	7K	0	34.48M	0	211K	1.41M	0
Long-Term Debt	0	0	0	0	0	33.17M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	853K	0	0	99K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	59.07M	59.06M	109.35M	7K	0	457K	0	211K	1.31M	0
Total Liabilities	59.84M	71.49M	123.9M	9.55M	10.66M	56.25M	18.41M	9.56M	8.95M	14.82M
Total Debt+	0	0	0	0	700K	34.78M	349K	0	214K	99K
Net Debt	-43.81M	-4.03M	-10.21M	-49.51M	-30.08M	-22.78M	-41.9M	-30.91M	-30.41M	-19.83M
Debt / Equity	-	-	-	-	0.01x	0.93x	0.01x	-	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	0.14x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-0.09x	-	-	-	-
Interest Coverage	-	-	-	-	-82.78x	57.53x	-6.94x	-	-	-
Total Equity+	-15.95M	-29.44M	-57.03M	130.38M	68.51M	37.49M	48.64M	31.2M	88.73M	52.09M
Equity Growth %	-	-0.85%	-0.94%	3.29%	-0.47%	-0.45%	0.3%	-0.36%	1.84%	-0.41%
Book Value per Share	-99.54	-97.30	-199.39	433.21	145.33	20.82	17.01	9.79	8.64	1.22
Total Shareholders' Equity	-15.95M	-29.44M	-57.03M	130.38M	68.51M	37.49M	48.64M	31.2M	88.73M	52.09M
Common Stock	1K	1K	1K	3K	3K	4K	5K	0	1K	1K
Retained Earnings	-16.05M	-30.11M	-59.19M	-110.64M	-184.34M	-566.2M	-639.52M	-662.74M	-691.34M	-731.17M
Treasury Stock	0	-699K	0	0	0	0	0	0	0	0
Accumulated OCI	-59M	-26K	-51K	-96K	24K	0	0	0	26K	20K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.18M	-2.29M	-28.25M	-52.73M	-65.1M	-137.08M	-56.37M	-29.2M	-25.34M	-33.97M
Operating CF Margin %	-	-3.4%	-6.16%	-4.96%	-146.95%	-6.53%	-60.54%	-61.22%	-59.77%	-67.81%
Operating CF Growth %	-	0.45%	-11.33%	-0.87%	-0.23%	-1.11%	0.59%	0.48%	0.13%	-0.34%
Net Income	-4.61M	-14.07M	-29.08M	-51.45M	-73.7M	-255.57M	-73.33M	-23.21M	-28.45M	-39.83M
Depreciation & Amortization	0	4K	8K	22K	700K	341K	109K	72K	0	4K
Stock-Based Compensation	65K	573K	1.45M	3.64M	6.7M	18.1M	8.08M	4.3M	3.31M	3.3M
Deferred Taxes	0	-573K	60K	0	0	56.3M	1.52M	0	0	0
Other Non-Cash Items	65K	705K	31K	-774K	-691K	84.07M	2.47M	-12.64M	-254K	-2.44M
Working Capital Changes	360K	11.07M	-722K	-4.17M	1.89M	-40.33M	4.78M	2.28M	60K	5M
Change in Receivables	0	0	-786K	786K	1.36M	-17.14M	7.71M	11.21M	405K	-899K
Change in Inventory	0	0	1.19M	2.76M	-1.36M	-6.05M	113K	97K	0	0
Change in Payables	0	889K	620K	825K	481K	-12.97M	-2.67M	-8.68M	-559K	6.01M
Cash from Investing+	0	-37.49M	-15.06M	-33.88M	41.37M	89.11M	1.03M	15.67M	-57.35M	23.36M
Capital Expenditures	0	-31K	-27K	-140K	-11K	-113K	0	0	0	-117K
CapEx % of Revenue	-	0.05%	0.01%	0.01%	0.02%	0.01%	-	-	-	0.23%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	25K	0	-40K	38.64M	0	0	0	0
Cash from Financing+	47.72M	0	49.49M	125.91M	4.99M	61.81M	39.78M	1.65M	82.39M	-141K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	98K	0	-833K	496K	465K	169K	228K	-28K	-67K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.18M	-2.32M	-28.27M	-52.87M	-65.11M	-137.19M	-56.37M	-29.2M	-25.34M	-34.09M
FCF Margin %	-	-3.45%	-6.17%	-4.97%	-146.98%	-6.54%	-60.54%	-61.22%	-59.77%	-68.04%
FCF Growth %	-	0.44%	-11.18%	-0.87%	-0.23%	-1.11%	0.59%	0.48%	0.13%	-0.35%
FCF per Share	-26.10	-7.67	-98.85	-175.68	-138.13	-76.18	-19.72	-9.17	-2.47	-0.80
FCF Conversion (FCF/Net Income)	0.91x	0.16x	0.97x	1.03x	0.92x	0.54x	0.77x	1.26x	0.89x	0.85x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-140.29%	-70.86%	-482.2%	-170.28%	-58.14%	-47.44%	-56.57%
Return on Invested Capital (ROIC)	-	-	-	-600.3%	-95.86%	712.8%	-272.12%	-731.86%	-74.86%	-72.26%
Gross Margin	-	100%	100%	100%	20.99%	93.37%	100%	100%	100%	100%
Net Margin	-	-2087.24%	-634.57%	-483.51%	-15906.09%	-1217.4%	-7876.37%	-4865.83%	-6710.38%	-7950.9%
Debt / Equity	-	-	-	-	0.01x	0.93x	0.01x	-	0.00x	0.00x
Interest Coverage	-	-	-	-	-82.78x	57.53x	-6.94x	-	-	-
FCF Conversion	0.91x	0.16x	0.97x	1.03x	0.92x	0.54x	0.77x	1.26x	0.89x	0.85x
Revenue Growth	-	-	579.82%	132.21%	-95.84%	4638.83%	-95.57%	-48.76%	-11.11%	18.16%

Revenue by Segment

	2020	2021	2022	2024
Reportable	-	-	-	501K
Reportable Growth	-	-	-	-
Royalty	791K	931K	477K	-
Royalty Growth	-	17.70%	-48.76%	-
Product	10.2M	13.82M	-	-
Product Growth	-	35.50%	-	-
License	10M	-	-	-
License Growth	-	-	-	-
Product and Service, Other	-	-	-	-
Product and Service, Other Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

VYNE Therapeutics Inc. (VYNE) reported $0.5M in revenue for fiscal year 2024.

VYNE Therapeutics Inc. (VYNE) grew revenue by 18.2% over the past year. This is strong growth.

VYNE Therapeutics Inc. (VYNE) reported a net loss of $33.7M for fiscal year 2024.

Dividend & Returns

VYNE Therapeutics Inc. (VYNE) has a return on equity (ROE) of -56.6%. Negative ROE indicates the company is unprofitable.

VYNE Therapeutics Inc. (VYNE) had negative free cash flow of $38.5M in fiscal year 2024, likely due to heavy capital investments.